Decheng Capital LLC bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,285,293 shares of the company's stock, valued at approximately $54,010,000. Upstream Bio makes up about 11.6% of Decheng Capital LLC's holdings, making the stock its 3rd biggest position. Decheng Capital LLC owned about 6.13% of Upstream Bio as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. US Bancorp DE acquired a new position in Upstream Bio during the fourth quarter worth about $27,000. Legal & General Group Plc bought a new position in Upstream Bio in the 4th quarter valued at approximately $28,000. Summit Investment Advisors Inc. bought a new position in Upstream Bio in the 4th quarter valued at approximately $30,000. Tower Research Capital LLC TRC bought a new position in Upstream Bio in the 4th quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. bought a new position in Upstream Bio in the 4th quarter valued at approximately $142,000.
Upstream Bio Price Performance
NASDAQ:UPB traded down $0.28 on Thursday, hitting $8.98. The company had a trading volume of 134,231 shares, compared to its average volume of 322,164. The firm has a 50 day moving average of $7.92 and a two-hundred day moving average of $14.33. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
